Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
:CTSO
CTSO Stock Chart & Stats
$0.71
-$0.05(-4.55%)
At close: 4:00 PM EST
$0.71
-$0.05(-4.55%)
Day’s Range― - ―
52-Week Range$0.60 - $1.61
Previous CloseN/A
Volume86.19K
Average Volume (3M)112.62K
Market Cap
$47.10M
Enterprise Value$78.50M
Total Cash (Recent Filing)$10.20M
Total Debt (Recent Filing)$27.06M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding62,804,306
10 Day Avg. Volume112,612
30 Day Avg. Volume112,623
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)4.46
Price to Sales (P/S)1.39
P/FCF Ratio-3.37
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue2.17
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda-4.74
Forecast
1Y Price Target
$0.75Price Target Upside5.63% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Direct Sales ExpansionDirect sales in territories outside Germany grew 23.5% to $8.8M, highlighting successful market penetration.
Global Distribution GrowthRevenue from global distribution partners grew 14.4% year-over-year to $15.6M, indicating strong international expansion.
New Application DevelopmentThe new De Novo application is expected to include analyses of real world data demonstrating DrugSorb-ATR’s effectiveness.
Bears Say
FDA Submission ChallengesThe FDA denied the company’s appeal and upheld the rejection of the previous submission for DrugSorb-ATR.
German Market PerformanceCommercial sales in Germany, the company’s most important market, continues to be a drag on revenue growth.
Revenue ExpectationsDue to the continued drag on Germany revenues, revenue expectations for 2025 and 2026 have been lowered.
Cytosorbents News
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.60 and its highest was $1.61 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $47.10M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Mar 05, 2026 which is in 92 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Nov 13, 2025. The company reported -$0.04 earnings per share for the quarter, the consensus estimate of -$0.04 by $0.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.05.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,804,306 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.04 in its last earnings report, expectations of -$0.04. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
Cytosorbents Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.87%
12-Months-Change
Fundamentals
Return on Equity
-96.15%
Trailing 12-Months
Asset Growth
-4.30%
Trailing 12-Months
Company Description
Cytosorbents Corp
Cytosorbents Corporation (CTSO) is a biomedical company focused on developing innovative therapies for critical care and other medical applications. The company specializes in blood purification technologies, primarily through its flagship product, CytoSorb, which is designed to remove cytokines and other harmful substances from the bloodstream. Cytosorbents operates in the healthcare sector, targeting hospitals and medical facilities with its advanced technologies aimed at improving patient outcomes in conditions such as sepsis, trauma, and cardiac surgery.
CTSO Company Deck
CTSO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and gross margin improvements, as well as strategic steps towards achieving profitability and regulatory progress in the U.S. However, challenges persist with declining sales in Germany and an increased net loss. The overall sentiment is cautiously optimistic as the company addresses these issues.View all CTSO earnings summariesCTSO Stock 12 Month Forecast
Average Price Target
$0.75
▲(5.63% Upside)
Technical Analysis
Ownership Overview
5.77% Insiders
5.79% Mutual Funds
15.26% Other Institutional Investors
70.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---